FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENTRevenue Interest Financing Agreement • June 6th, 2024 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”) is entered into as of June 6, 2024, by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Partners FUNDING Borrower SPE 1, lp, a Delaware limited partnership (as successor in interest by assignment to Sagard Healthcare Partners (Delaware) LP, a Delaware limited partnership (as successor in interest by assignment to Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership)) (the “Investor”).
SECOND AMENDMENT TO CREDIT AGREEMENTCredit Agreement • June 6th, 2024 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of June 6, 2024 (this “Amendment”), to that certain Credit Agreement dated as of May 11, 2021 (as amended by the Limited Consent and First Amendment to Credit Agreement, dated as of October 28, 2022, and as further amended, modified and restated from time to time prior to the date hereof, the “Existing Credit Agreement” and, the Existing Credit Agreement, as amended by this Amendment, the “Credit Agreement”), by and among MARINUS PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), certain Subsidiaries of the Borrower that may be required to provide Guarantees from time to time thereunder (each a “Guarantor” and collectively, the “Guarantors”), the lenders from time to time thereunder (each a “Lender” and collectively, the “Lenders”), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”) is entered into by and among the Borrower, the Administrative Agent and
